Glycine transport inhibitors for the treatment of schizophrenia.
Multiple lines of evidence indicate that hypofunction of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia, suggesting that increasing NMDA receptor function via pharmacological manipulation could provide a new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) shows antipsychotic activity in patients with schizophrenia. Accordingly, a number of pharmaceutical companies have developed novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. This paper provides an overview of the various GlyT-1 inhibitors and their therapeutic potential.
Division of Clinical Neuroscience, Chiba University Center for Forensic, Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan.
Kenji
K
Hashimoto
Psychopharmacology (Berl). 2009 Jan;202(1-3):385-96
18709358
Neuropsychopharmacology. 2005 Nov;30(11):1963-85
15956994
Curr Opin Pharmacol. 2006 Feb;6(1):75-81
16376148
Neuropsychopharmacology. 1999 Mar;20(3):201-25
10063482
Nature. 1967 Sep 30;215(5109):1502-3
4293850
Neuropharmacology. 2003 Oct;45(5):585-93
12941372
Psychopharmacology (Berl). 2008 Dec;201(2):273-84
18704372
Eur J Neurosci. 2008 Oct;28(7):1342-50
18973561
Trends Biochem Sci. 2005 Jun;30(6):325-33
15950877
Alcohol Alcohol. 2007 Jan-Feb;42(1):11-8
17098748
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4321-5
16762550
Trends Pharmacol Sci. 2005 Jun;26(6):283-6
15925702
Schizophr Res. 2004 Feb 1;66(2-3):89-96
15061240
J Neurosci. 2003 Aug 20;23(20):7586-91
12930797
Science. 1969 May 2;164(3879):571-2
4388476
Expert Opin Investig Drugs. 2004 May;13(5):515-21
15155126
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
16894061
Am J Psychiatry. 1978 Sep;135(9):1081-4
696930
Nature. 2009 Feb 12;457(7231):910-4
19212411
Eur Neuropsychopharmacol. 2009 Dec;19(12):861-7
19656663
Neuron. 2003 Nov 13;40(4):785-96
14622582
ChemMedChem. 2006 Aug;1(8):807-11
16902933
Bioorg Med Chem Lett. 2006 Dec 1;16(23):5968-72
16987662
Annu Rev Pharmacol Toxicol. 2002;42:165-79
11807169
Br J Pharmacol. 2001 Dec;134(7):1429-36
11724748
Harv Rev Psychiatry. 1996 Jan-Feb;3(5):241-53
9384954
Bioorg Med Chem Lett. 2006 Aug 1;16(15):3981-4
16725323
Mol Neurobiol. 1997 Jun;14(3):117-42
9294860
Brain Res Rev. 2009 Oct;61(2):105-23
19481572
Arch Gen Psychiatry. 1995 Dec;52(12):998-1007
7492260
Curr Opin Investig Drugs. 2002 Jul;3(7):1067-72
12186269
Curr Psychiatry Rep. 2007 Dec;9(6):467-74
18221626
Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78
19562643
Arch Gen Psychiatry. 2007 Dec;64(12):1368-76
18056544
Arch Gen Psychiatry. 2005 Nov;62(11):1196-204
16275807
Mol Pharmacol. 2001 Dec;60(6):1414-20
11723250
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4305-10
16762548
Psychopharmacology (Berl). 2005 Apr;179(1):54-67
15759151
J Psychopharmacol. 2010 Nov;24(11):1681-7
19648218
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):336-9
17884273
Neuron. 1993 May;10(5):851-63
8494645
J Biol Chem. 1993 Jan 25;268(3):2106-12
8420981
Psychopharmacology (Berl). 2004 Jun;174(1):32-8
15205876
Schizophr Res. 1993 Jan;8(3):233-43
8435385
Am J Psychiatry. 1991 Oct;148(10):1301-8
1654746
Neuropsychopharmacology. 1995 Aug;13(1):9-19
8526975
Mol Pharmacol. 1994 Apr;45(4):608-17
8183239
Pharmacol Biochem Behav. 2008 Nov;91(1):47-58
18621075
Neurosci Lett. 1990 Dec 11;120(2):237-40
2127307
Bioorg Med Chem Lett. 2008 Sep 15;18(18):5134-9
18752953
Cereb Cortex. 2005 Apr;15(4):448-59
15749988
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15730-4
9861038
AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363-9
13626287
Eur Neuropsychopharmacol. 2008 Jun;18(6):414-21
17804206
Am J Psychiatry. 2001 Sep;158(9):1367-77
11532718
Expert Opin Ther Targets. 2001 Aug;5(4):507-518
12540263
Biol Psychiatry. 2008 Jan 1;63(1):9-12
17659263
Nature. 2009 Feb 12;457(7231):799-800
19212391
Neuron. 1992 May;8(5):927-35
1534013
Curr Top Med Chem. 2006;6(17):1883-96
17017963
J Neurosci. 1995 May;15(5 Pt 2):3952-69
7751957
Neuropsychopharmacology. 2007 Mar;32(3):514-21
16495935
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8485-90
15159536
Brain Res. 2009 Jul 7;1279:189-96
19433073
Life Sci. 1965 Nov;4(21):2075-83
5866625
Neuroscience. 2006;137(2):555-64
16289893
Arch Gen Psychiatry. 2003 Jun;60(6):572-6
12796220
Pharmacol Ther. 2008 Dec;120(3):317-32
18805436
Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):191-213
12769627
Recent Pat CNS Drug Discov. 2006 Jan;1(1):43-53
18221190
Behav Brain Res. 2008 Jan 10;186(1):78-83
17854919
Pharmacol Rev. 1998 Dec;50(4):597-664
9860805
Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7
16099452
Bioorg Med Chem Lett. 2004 Aug 2;14(15):4027-30
15225720
Bioorg Med Chem Lett. 2006 Jan 15;16(2):354-7
16246561
Biol Psychiatry. 2006 Sep 15;60(6):645-9
16780811
Bioorg Med Chem Lett. 2006 Jan 15;16(2):349-53
16246557
Clin Pharmacol Ther. 1995 Aug;58(2):165-73
7648766
Eur Neuropsychopharmacol. 2009 Aug;19(8):571-80
19282154
Biol Psychiatry. 2008 Jan 1;63(1):6-8
18082555
Pharmacol Ther. 2009 Aug;123(2):143-50
19397926
Biol Psychiatry. 2004 Mar 1;55(5):452-6
15023571
Biol Psychiatry. 2008 Jan 1;63(1):92-7
17601496
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
8122957
Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54
18164909
Eur J Pharmacol. 2006 Dec 28;553(1-3):191-5
17094961
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4311-5
16757170
Curr Opin Pharmacol. 2005 Feb;5(1):101-6
15661633
J Physiol. 2009 Jul 1;587(Pt 13):3207-20
19433577
Nucl Med Biol. 2008 Apr;35(3):315-25
18355687
Neuropsychopharmacology. 1996 May;14(5):301-7
8703299
Eur J Neurosci. 1995 Jun 1;7(6):1342-52
7582108
Harv Rev Psychiatry. 1999 Sep-Oct;7(3):125-43
10483932